Background: Anti-Mullerian hormone (AMH) is vital in the pathophysiological process of polycystic ovary syndrome (PCOS). The exact relationship between obesity and insulin resistance (IR) with AMH levels remains unclear. Methods: A retrospective, single-center cohort study of 220 women with PCOS who underwent physical, endocrine, and metabolic assessments were performed. Patients were grouped by age, body mass indices (BMI), Homeostatic Model Assessment of Insulin Resistance (HOMA-IR), and different phenotypes. Pearson correlation analysis assessed the correlation between AMH and HOMA-IR, BMI, and other PCOS indicators, and multiple linear regression analysis was performed to determine factors influencing AMH. Results: In 220 patients with PCOS, serum AMH levels decreased with age and were significantly higher in the IR group than in the non-IR group (P < 0.01). AMH increased significantly in anovulatory patients with hyperandrogenemia and/or polycystic ovary, with no significant difference between obese and non-obese individuals. AMH levels correlated positively with luteinizing hormone (LH), LH/follicular stimulating hormone (FSH), testosterone, fasting insulin (FINS), and HOMA-IR levels; negatively with age and BMI levels (P < 0.05) and weakly with fasting plasma glucose in the classical PCOS phenotype (r=0.148, P < 0.05). Regression analysis showed that age, testosterone, FINS, LH, LH/FSH, and BMI influenced AMH levels (P < 0.05). Conclusion: Chinese women with PCOS-IR showed associations with greater AMH levels. AMH levels correlated positively with HOMA-IR levels and negatively with BMI. AMH combined with BMI and HOMA-IR levels may help determine PCOS severity.

Autoimmune thyroiditis (AITD) is a T-cell-mediated, organ- specific autoimmune disease caused by interactions between genetic and environmental factors. Patients with AITD show thyroid lymphocyte infiltration and an increase in the titer of thyroid autoimmune antibodies, thereby altering the integrity of thyroid follicle epithelial cells and dysregulating their metabolism and immune function, leading to a decrease in multi-tissue metabolic activity. Research has shown that patients with AITD have a significantly higher risk of adverse pregnancy outcomes, such as infertility and miscarriage. Levothyroxine(LT₄) treatment can improve the pregnancy outcomes of normal pregnant women with thyroid peroxidase antibodies(TPOAb) positivity, but it is not effective for invitro fertilization embryo transfer (IVF-ET) in women with normal thyroid function and positive TPOAb. Other factors may also influence pregnancy outcomes of patients with AITD. Recent studies have revealed that the gut microbiota participates in the occurrence and development of AITD by influencing the gut-thyroid axis. The bacterial abundance and diversity of patients with Hashimoto thyroiditis (HT) were significantly reduced, and the relative abundances of Bacteroides, fecal Bacillus, Prevotella, and Lactobacillus also decreased. The confirmation of whether adjusting the composition of the gut microbiota can improve pregnancy outcomes in patients with AITD is still pending. This article reviews the characteristics of the gut microbiota in patients with AITD and the current research on its impact in pregnancy.

Gestational diabetes mellitus is one of the most common endocrine diseases that occur during pregnancy. Disorders of blood glucose metabolism during pregnancy can increase the risk of adverse pregnancy outcomes, such as pregnancy-related hypertension, preeclampsia, eclampsia, miscarriage, macrosomia, and neonatal hypoglycemia. Continuous glucose monitoring (CGM) can safely and effectively monitor blood glucose changes in patients with gestational hyperglycemia, thereby reducing adverse pregnancy outcomes. Hence, this article aimed to provide a comprehensive review of the progress and indications for using CGM in pregnant patients with diabetes. CGM can reduce blood glucose fluctuations and the occurrence of serious hypoglycemia and hyperglycemia events and can provide time in range (TIR). TIR is an important indicator of blood glucose level. Patients with a higher TIR during pregnancy have better gestational outcomes.

Objectives To analyse and explore the association between thyroid autoantibodies and diabetic kidney disease (DKD) in patients with type 2 diabetes mellitus (T2DM). Design A cross-sectional study. Setting Patients were from the inpatient unit at The Second Endocrinology Department of Shengjing Hospital Affiliated to China Medical University (Shenyang, China) between January 2015 and September 2019. Participants A total of 150 Chinese adults with T2DM were included in the study, including 83 men and 67 women. Their age ranged between 25 and 92 years. Methodology They grouped by the presence of DKD, urine albumin-to-creatinine ratio (UACR), estimated glomerular filtration rate, and levels of thyroid peroxidase antibodies (TPOAb) and thyroglobulin antibodies (TgAb). Data on the patients’ general characteristics and laboratory measurements (levels of fasting plasma glucose, glycated haemoglobin, and albumin; renal function; and thyroid function) were collected. Binary logistic regression was performed to identify risk factors for DKD. Results The level of TPOAb, the positivity rates of TPOAb (p<0.01) and TgAb (p<0.05) were higher in patients with DKD than in those without DKD. The TPOAb level in patients with a UACR<30 mg/g creatinine was lower than that in patients with a UACR between 30 and 300 mg/g creatinine (p<0.05). The prevalence of DKD was higher in patients with a TPOAb-positive or TgAb-positive status. The result of binary logistic regression analysis showed that a TPOAb-positive status was significantly associated with DKD in patients with T2DM (OR=7.683, 95% CI 1.583 to 37.286, p<0.05). Conclusions TPOAb-positive status is in association with DKD in patients with T2DM. Large scale, prospective cohort studies are warranted to confirm our findings.

Cadmium (Cd), a ubiquitous environmental pollutant, exhibits potential neurotoxic risk. While compelling evidence links Cd accumulation to the pathogenesis of Alzheimer's disease (AD), the global impact of blood Cd exposure on AD mortality remains underexplored. We conducted an extensive review of 102 studies from 30 countries and standardized blood Cd concentrations to estimate the geometric mean (GM) and geometric standard deviation (GSD) of Cd exposure. Estimated annual percentage change (EAPC) was calculated to assess the trend in AD mortality, with 1000 Monte Carlo simulations to estimate population attributable fractions (RAF). The augmented human development index (AHDI) was used to analyze correlations with Cd-related mortality. Bayesian hierarchical regression models revealed a 72% reduction in GM in Egypt, contrasted by a 142% increase in Australia. Germany and Brazil demonstrated significant GM reductions along with increased GSD, reflecting regional variability. Conversely, Japan and South Korea exhibited marked rises in the regional variability, while Egypt and France achieved significant reductions in Cd-related AD deaths for both males and females, reaching zero by 2020. The number of deaths related to Cd in Australia and Japan has increased. While countries like Norway, Germany, and Lithuania showed declining mortality trends, others (e.g., Poland and Italy), exhibited rising mortality despite AHDI improvements. This study represents the first comprehensive assessment of the global burden of AD attributable to blood Cd exposure, reveal significant regional disparities. It provides epidemiological references for policymakers to formulate Cd management strategies and guides researchers in selecting impactful study directions.

BackgroundAnti-Mullerian Hormone (AMH) has an important role in the pathophysiological process of polycystic ovary syndrome (PCOS) by regulating follicular development and is closely related to the severity of PCOS. Previous studies have suggested that AMH levels in PCOS is related to hyperandrogenemia levels and are affected by obesity and insulin resistance. however, the exact relationship between AMH levels and obesity and insulin resistance remains unclear. We aimed to elucidate the relationship between insulin resistance and obesity and serum AMH levels in women with PCOS. MethodsWe conducted a retrospective study of 220 women with PCOS who had undergone an assortment of physical, endocrine, and metabolic assessments. AMH levels and various other indicators of PCOS in patients with different body mass indices (BMI) and Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) levels were compared. Independent sample t-tests were performed to compare two groups. Pearson correlation analysis was performed to study the correlation between AMH and age, obesity, IR, and other indicators of PCOS, and multiple linear regression analysis was performed to determine the factors influencing AMH. Bilateral tests were performed for all statistical tests. The data were analysed using SPSS v25.0. Statistical significance was defined as a two-sided P-value of less than 0.05.ResultsWe found that >50% of patients with PCOS had insulin resistance, obesity, hyperandrogenemia, and abnormal glucose tolerance. AMH, testosterone (T), and HOMA-IR levels were affected by age, and older participants had lower AMH, HOMA-IR, and androgen levels (P < 0.05). Glycated hemoglobin levels were higher and AMH, luteinizing hormone (LH)/follicle-stimulating hormone (FSH), and LH levels were lower in non-obese individuals than in obese individuals (both P < 0.05). Participants in the non-insulin resistant (IR; NIR) group were older than those in the IR group (P < 0.05). AMH, LH, LH/FSH, and T levels in the IR group were significantly higher than those in the NIR group (P < 0.05). AMH levels were positively correlated with LH, LH/FSH, T, fasting insulin (FINS), and HOMA-IR levels as well as the free androgen index and negatively correlated with age, BMI, and sex hormone binding globulin levels (P < 0.05). Through multiple linear regression, we found that AMH levels could be explained by T, LH/FSH, FINS, sex hormone binding globulin, LH levels, and BMI.ConclusionsSerum AMH levels were closely related to metabolic abnormalities in PCOS. In patients with PCOS, AMH levels were positively correlated with HOMA-IR levels and negatively correlated with BMI. Thus, AMH combined with BMI and HOMA-IR levels could help determine the severity of PCOS.